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Abstract 
The three anti‑malarial drugs artemiside, artemisone, and mefloquine, and the naphthoquinone buparvaquone 
known to be active against theileriosis in cattle and Leishmania infections in rodents, were assessed for activity against 
Neospora caninum infection. All four compounds inhibited the proliferation of N. caninum tachyzoites in vitro with IC50 
in the sub‑micromolar range, but artemisone and buparvaquone were most effective (IC50 = 3 and 4.9 nM, respec‑
tively). However, in a neosporosis mouse model for cerebral infection comprising Balb/c mice experimentally infected 
with the virulent isolate Nc‑Spain7, the three anti‑malarial compounds failed to exhibit any activity, since treatment 
did not reduce the parasite burden in brains and lungs compared to untreated controls. Thus, these compounds were 
not further evaluated in pregnant mice. On the other hand, buparvaquone, shown earlier to be effective in reducing 
the parasite load in the lungs in an acute neosporosis disease model, was further assessed in the pregnant mouse 
model. Buparvaquone efficiently inhibited vertical transmission in Balb/c mice experimentally infected at day 7 of 
pregnancy, reduced clinical signs in the pups, but had no effect on cerebral infection in the dams. This demonstrates 
proof‑of‑concept that drug repurposing may lead to the discovery of an effective compound against neosporosis 
that can protect offspring from vertical transmission and disease.
© 2016 Müller et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Neospora caninum is a cyst-forming apicomplexan para-
site closely related to Toxoplasma gondii. N. caninum is 
one of the most important infectious causes of bovine 
abortion, stillbirth, and the birth of weak calves, with 
an economic impact of over 1.3 billion US dollars [1–3]. 
N. caninum infection can also result in birth of clinically 
healthy, but persistently infected calves transmitting the 
parasite to the next generation. In addition, N. caninum 
causes neuromuscular disease in dogs, and neosporosis 
has also been detected in a wide range of other species of 
livestock and wild animals worldwide.
Possible strategies to limit the economic impact of 
neosporosis include testing and culling of seropositive 
animals, discontinued breeding with offspring from sero-
positive cows, vaccination of susceptible and infected 
animals, and chemotherapeutical treatment of calves 
from seropositive cows [4, 5]. However, the most effective 
option is not always the most economic one [6] and the 
suitability of any of these options has to be assessed [6, 7].
As is the case for neglected diseases, one option for 
chemotherapy of neosporosis in cattle is the repurpos-
ing of drugs with well-documented antiparasitic activi-
ties [8–10]. The most prominent compounds in this 
context are certainly antimalarial drugs, for which enor-
mous screening campaigns have been initiated, such as the 
high-throughput screening efforts of St. Jude Children’s 
Research Hospital (TN, USA), Novartis and GlaxoSmith-
Kline [11–13]. While such large screening campaigns 
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cannot be carried out for N. caninum, simply due to the 
lack of resources, one possibility is to use a piggy-back 
approach and perform efficacy testing of selected drugs 
that are already either marketed or in clinical trials for 
human and/or veterinary use. By screening a larger panel 
of such compounds, we here report on the results obtained 
with the three antimalarials artemisone, artemiside, and 
mefloquine, and the naphthoquinone buparvaquone.
Artemisone and artemiside are artemisinin deriva-
tives [14] that have shown promising efficacy against 
experimentally induced toxoplasmosis in mice [15]. 
Moreover, artemisone is highly active against N. cani-
num tachyzoites in vitro [16] and was shown to protect 
gerbils against cerebral infection [17]. Artemiside exhib-
its excellent efficacy against malaria in a murine model 
[18], but has not been tested against neosporosis so far. 
Mefloquine, one of the most common antimalarials [19], 
is active in a mouse model of Schistosoma mansoni infec-
tion [20] and shows promising results in Echinococcus 
multilocularis infected mice [21], but its effect against 
N. caninum has never been assessed. Buparvaquone was 
also originally developed as an anti-malarial compound 
[22] and is now commercially available (Butalex®), for 
use in endemic regions against theileriosis in cattle. In 
other regions of the world, e.g., the EU, it is, however, 
not registered. In most cases only a single dose injec-
tion is required to cure Theileria-infected animals within 
a few days, with cure rates near to 100% when adminis-
tered at the early stages of clinical disease [23]. The mode 
of action of buparvaquone has not been clarified, but 
there are indications that it blocks the parasite respira-
tory chain [22], and resistance against buparvaquone has 
been associated with mutations in the cytochrome b gene 
of the parasite [24, 25]. Besides exhibiting an outstand-
ing activity against Theileria spp. [26, 27], buparvaquone 
is also active against other protozoan parasites includ-
ing Leishmania spp. [28] and Babesia spp. [29]. Moreo-
ver, buparvaquone is highly active against N. caninum 
in  vitro, and in a non-pregnant mouse model for acute 
disease we have recently shown that buparvaquone treat-
ment protects mice against infection in the lungs, but not 
the brain, and prevents clinical signs of acute disease [30].
Here we applied a standardized Balb/c mouse model 
infected with the N. caninum NcSpain-7 isolate [31] to 
demonstrate that of these four compounds buparvaquone 
may have the potential to limit vertical transmission in N. 
caninum infected animals without inducing detrimental 
effects on pregnancy.
Materials and methods
Tissue culture media, biochemicals, and drugs
If not stated otherwise, all tissue culture media were 
purchased from Gibco-BRL (Zürich, Switzerland), and 
biochemical reagents were from Sigma (St. Louis, MO, 
USA). Kits for molecular biology were purchased from 
Qiagen (Hilden, Germany). Buparvaquone was provided 
by Cross Vetpharm Group Limited (Dublin, Ireland). 
Mefloquine was kindly supplied by Mepha Pharma AG 
(Aesch BL, Switzerland). Artemiside was synthesized 
according to the literature procedure [18] and artemisone 
was purified and supplied by Cipla Mumbai Ltd.
Host cell cultivation and parasite cultures
Tachyzoites of the N. caninum Nc-Spain7 isolate were 
cultured and prepared for infection as described [31].
In vitro efficacy
In vitro efficacies of the compounds were determined 
using a N. caninum beta-galactosidase reporter strain 
(Nc-beta-gal) and human foreskin fibroblasts (HFF) as 
host cells. Briefly, HFF were seeded into 96-well-plates, 
grown to confluence, and infected with 103 Nc-beta-gal-
tachyzoites per well in the presence of the compound to 
be tested or DMSO as a solvent control. After 3  days, 
medium was removed, and after one wash with PBS, cells 
were overlaid with 0.1 mL PBS containing Triton-X-100 
(0.05%) and chlorophenyl-red-beta-galactoside (Roche, 
Rotkreuz, Switzerland). Absorption was continuously 
read at 570 nm using a 96-well-plate spectrophotometer 
(Versamax, Molecular Devices, Sunnyvale CA) [16]. Host 
cell toxicity was determined by Alamar blue as described 
[30].
Animal experimentation
All protocols involving animals were approved by the 
Animal Welfare Committee of the Canton of Bern under 
the license BE115/14. All animals used in this study were 
handled in strict accordance with practices made to min-
imize suffering. Female and male BALB/c mice, 8 weeks 
of age, were purchased from a commercial breeder 
(Charles River, Sulzberg, Germany), and were maintained 
in a common room under controlled temperature and a 
14  h/10  h light cycle according to the guidelines set up 
by the animal welfare legislation of the Swiss Veterinary 
Office (approval No. BE 105/14).
Assessment of the effects of mefloquine, artemisone, 
and artemiside on male BALB/c mice infected with N. 
caninum Spain‑7
Male Balb/c mice were randomly distributed in four 
groups of six mice each and subcutaneously infected with 
105 tachyzoites of the Nc-Spain7 isolate. At day 2 post 
infection (pi), one group received corn oil alone (placebo 
control), the others received mefloquine, artemiside, or 
artemisone (50 mg/kg/day suspended in 100 µL corn oil) 
for a period of 6 days by gavage once a day. At day 21 pi, 
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the mice were euthanized. Blood was recovered by car-
diac puncture and sera were obtained to assess humoral 
immune responses. Brains and lungs were removed for 
subsequent determination of parasite load and stored at 
−20 °C until further processing.
Assessment of the effects of buparvaquone 
on non‑pregnant and pregnant BALB/c mice infected 
with N. caninum Spain‑7
Fourty-eight female and 24 male BALB/c mice were 
housed, and pregnancy was achieved after synchroni-
zation of oestrus [31]. Subsequently, female mice were 
randomly distributed in 3 groups of 16 mice each. Mice 
from group 1 and 2 were subcutaneously infected with 
105 tachyzoites of the Nc-Spain7 isolate at mid gesta-
tion (days 7 after mating), while mice from group 3 were 
left uninfected and received a culture medium inocu-
lation [31] At day 2 pi, all mice from group 1 received 
buparvaquone (50 mg/kg/day suspended in 100 µL corn 
oil) for a period of 6 days by gavage once a day, while the 
group 2 mice received corn oil alone. Prior to gavage, the 
corn oil-drug mixture was heated to 37  °C to enhance 
solubility of the drug. Group 3 remained untouched. 
Pregnancy was confirmed between days 15–18 of gesta-
tion by weighing, and pregnant mice were then allocated 
into single cages to give birth on days 20–22 and to rear 
their pups for an additional 30  days. During this time, 
those females that had remained non-pregnant were 
maintained in cages of 3-5 mice. Non-pregnant mice 
were evaluated for clinical signs of disease twice daily 
and euthanized in a CO2 chamber latest at day 21 post 
infection. Concerning dams and pups, the litter size, i.e., 
the number of delivered pups per dam, early pup mortal-
ity defined as the number of full-term dead pups from 
birth until day 2 post partum (pp), post-natal mortality 
defined as the number of dead pups from day 3 to 30 
p.p., and clinical signs were recorded. Surviving dams 
and pups were euthanized at 30 days p.p. (thus 44 days 
pi). Blood was recovered by cardiac puncture and sera 
were obtained to assess humoral immune responses. 
Brains were removed for subsequent determination of 
parasite load and stored at −20 °C until further process-
ing. The set-up of the in  vivo experiments is shown in 
Table 1.
Analysis of biological samples from in vivo experiments
To quantify the parasite load in brains and lungs, DNA 
purification was performed employing the DNeasy Blood 
& Tissue Kit (Qiagen, Basel, Switzerland) according to the 
standard protocol suitable for animal tissues. The DNA 
concentrations in all samples were determined using the 
QuantiFluor dsDNA System (Promega, Madison, Wi., 
USA) according to the manufacturer’s instructions and 
adjusted with sterile DNAse free water to 5 ng/µL. Quan-
tification of parasite loads in brains and lungs was per-
formed as described [30, 32]. Serum titers for N. caninum 
were assessed by ELISA as described [33, 34].
Statistics
Statistical analysis of the parasite burdens in brains was 
done using the Kruskal–Wallis test followed by Wil-
coxon rank-sum-test. Survival analysis of the pups was 
performed on the corresponding Kaplan–Meier estima-
tor using the log-rank-test. Nominal data were analyzed 
using the Chi square test. All analyses were performed 
using the software package R [35].
Results
In vitro efficacies of artemisone, artemiside, mefloquine 
and buparvaquone against N. caninum tachyzoites
Prior to in vivo studies, the efficacies of artemisone, arte-
miside, mefloquine, and buparvaquone against the pro-
liferation of N. caninum tachyzoites in human foreskin 
fibroblasts were determined. Mefloquine and artemiside 
inhibited proliferation with a much higher IC50 than 
artemisone and buparvaquone as visualized by combin-
ing the inhibition curves of these four compounds at the 
same scale (Figure  1). In parallel, cytotoxicity of these 
four compounds on the human fibroblast host cells was 
assessed. Of these four compounds, only mefloquine 
showed a moderate host cell toxicity with an IC50 below 
5 µM, while the other three compounds exhibited toxic-
ity at concentrations only at concentrations above 5 µM 
(Table 2).
Table 1 Overview of animal experiments presented in this 
study
Balb/c mice were used throughout the experiment, either males for an in vivo 
pre-test of artemiside, artemisone or mefloquine (ARI, ARO, MEF; Exp I), or 
females for assessing the effectiveness of buparvaquone (BPQ) in a pregnant 
mouse model (Exp. II). pi, post infection with 105  NcSpain7 tachyzoites.
Exp I Exp II
Gender Males Females
Groups 4, 6 mice per group 3, 16 mice per group
Mating No Yes
Challenge Nc‑Spain 7 (105) Nc‑Spain 7 (105), 7 days post 
mating
Treatment ARI, ARO, MEF, placebo;  
days 2–7 pi
BPQ, placebo; days 2–7 pi
Euthanasia 21 days pi non‑pregnant: 21 days pi 
dams: 30 days after birth, 
i.e., 44 days pi
Parameters N. caninum load in brains 
and lungs, serum titer
Number of pups, N. caninum 
brain load, serum titer
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In vivo efficacies in a Balb/c mouse model for cerebral N. 
caninum infection
In order to investigate whether artemisone, artemiside 
and mefloquine also affected N. caninum infection, the 
three anti-malarials were applied in male BALB/c that 
were infected with 105 N. caninum Nc-Spain7 tachy-
zoites. Two days pi, treatment with artemiside, arte-
misone, or mefloquine (50 mg/g bw in corn oil), or with 
corn oil alone was initiated and continued over 6  days. 
All mice were euthanized at day 21 pi. None of the mice 
showed clinical signs at this stage. The treatments had 
no effect on parasite loads either in the brain (Figure 2A) 
or in the lungs (Figure 2B). As a consequence, studies on 
female mice that had been mated to assess the effects on 
vertical transmission of N. caninum were performed only 
with buparvaquone.
Treatment of pregnant mice with buparvaquone protects 
pups from vertical transmission of N. caninum
The results on the effects of buparvaquone treatment in 
pregnant mice are summarized in Table 3 and Figure 5. 
Buparvaquone had no significant effects on the repro-
ductive performance as assessed via determination of 
the pregnancy rate, the litter size and neonatal mortal-
ity (Table  3). After the dams had given birth, offspring 
and dams were maintained for 30 days in order to assess 
the long-term-impact during the post-natal phase in 
dams and offspring  (Figure  5). Whereas five of eight 
dams of the placebo control group showed clinical signs 
and one died before the end of the experiment, none of 
the buparvaquone treated dams showed clinical signs 
and none of them died before the end of the experi-
ment (Table 3). In all placebo treated dams and in six of 
Figure 1 Inhibition of N. caninum proliferation in vitro. Human 
foreskin fibroblasts (HFFs) were grown to confluence in 96‑well‑
plates, treated with the compounds at various concentrations or 
with DMSO as a solvent control and infected with Nc‑beta‑gal 
tachyzoites (103 per well). After 3 days, beta‑galactosidase activity was 
determined. Mean values ± SE are given for four wells relative to the 
solvent control.
Table 2 In vitro efficacies of  the compounds used in  this 
study
Human foreskin fibroblasts (HFF) were grown to confluence in 96-well-plates, 
treated with the compounds at various concentrations or with DMSO as a 
solvent control, and after 3 days viability was measured using the Alamar blue 
assay. To determine the inhibition of N. caninum (Nc) tachyzoite proliferation 
(Nc), HFF monolayers were infected with Nc-beta-gal tachyzoites (103 per well). 
After 3 days, beta-galactosidase activity was determined. IC50 values (inhibitory 
concentration of 50% of the solvent control value) were calculated as described 
[16] and are given in nM (with 95% confidence intervals).
Compound IC50 Nc IC50 HFF Reference
Artemiside 346 (308–388) >5000 This work
Artemisone 3 (1–13) >5000 [16]
Buparvaquone 4.9 (4.0–5.9) >5000 [30]
Mefloquine 941 (775–1141) 3643 (3062–4335) This work
Figure 2 Parasite load in brains and lungs of mice treated with 
artemiside, artemisone, or mefloquine. Male BALB/c mice were 
infected with Nc‑Spain7 tachyzoites and subsequently treated with 
artemiside (ARI), artemisone (ARO), mefloquine (MEF) in corn oil or 
corn oil only (Placebo) as detailed in Section “Materials and methods”. 
The mice were euthanized 3 weeks pi. After euthanasia, brains and 
lungs were collected and the amount of tachyzoites was determined 
by quantitative PCR and are presented as box plots (n = 6). A brains, 
B lungs.
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eight buparvaquone treated dams N. caninum DNA was 
detected in the brain by real time PCR (Table 3).
None of the non-pregnant mice exhibited clinical 
signs of neosporosis during 3  weeks following infec-
tion (Table  3). In the buparvaquone treated group, the 
brain parasite load ranged between 0 and 450 tachy-
zoites per µg DNA as compared to 2700 and 31 000 in 
the placebo control group. This difference was highly sig-
nificant (Figure 3A). After 44 days pi, however, in dams 
that had given offspring, the cerebral parasite loads in 
buparvaquone-treated dams did not significantly differ 
from the parasite loads in the placebo groups (Figure 3B). 
All mice that had been infected were seropositive as 
assessed by ELISA (Table 3). In the non-pregnant females 
treated with buparvaquone, the serum titer was, how-
ever, not as high as in the placebo group (Figure 4A). In 
the infected dams, the serum titers were, however, at the 
same levels (Figure 4B). 
For the offspring, two pups from the placebo group 
and one from the buparvaquone treated group died 
immediately after birth. During the next 28  days, 40 of 
the remaining 41 pups died in the control group, whereas 
only 18 of 45 in the buparvaquone-treated group died 
(Table 2). After 30 days, all survivors were tested by PCR 
for the presence of N. caninum in their brains. The last 
survivor from the placebo group was brain positive, as 
well as 7 out of 45 surviving pups from buparvaquone 
treated dams. Thus, mortality and transmission of N. 
caninum to pups were strongly reduced by buparvaquone 
treatment of the dams. The differences were highly signif-
icant (Table 2). This effect was even more apparent after 
analysis of the survival using the Kaplan–Meier-estima-
tor as survival parameter and by comparing the resulting 
survival curves using the log-rank-test (Figures 4 and 5).
Discussion
In order to investigate whether drug repurposing may 
be a suitable strategy for obtaining suitable chemothera-
peutic agents against neosporosis, we have tested four 
compounds, namely artemiside, artemisone, mefloquine, 
and buparvaquone, with proven efficacies against api-
complexan parasites in vitro and in mouse models. Three 
of these four compounds, artemiside, artemisone, and 
mefloquine did not affect the cerebral parasite load when 
assessed in a chronic infection model for N. caninum 
infection. This demonstrates that a low IC50 value against 
N. caninum tachyzoites obtained in vitro (in the case of 
artemisone; see also [16]) is not a predictive parameter 
for good in vivo effects. Moreover, our results are not in 
line with previous findings concerning effects of artemi-
sone against neosporosis in gerbils [17]. However, in that 
study artemisone was administered by intraperitoneal 
injection as a formulation solubilized in DMSO, and the 
authors used another isolate (NcIS491) from Israel [36], 
which most likely differs in virulence from the Nc-Spain7 
isolate used in this study. In a previous study on experi-
mentally induced murine toxoplasmosis, DMSO solu-
tions of artemisone and artemiside had been applied s.c. 
[15], but we refrained from this application mode due to 
potential side effects that is induced by this treatment 
based on own observations and on previously published 
results [37]. Oral application of mefloquine, shown to be 
effective against schistosomiasis [20] and more recently 
against Echinococcus infections in mice [38] did not 
exhibit any effects against N. caninum in this study.
Buparvaquone drastically limits the proliferation of 
N. caninum tachyzoites in  vitro. In addition, we have 
previously shown that administration of buparvaquone 
protected mice that were infected with a high dosage 
(2 × 106) of N. caninum tachyzoites of the Nc-Liverpool 
isolate against acute neosporosis [30]. In the present 
study, by using a 20 times reduced infection dose (105 
tachyzoites), which does not lead to acute symptoms 
Table 3 Effects of  buparvaquone treatment on  clinical 
signs, mortality, fertility and  cerebral N. caninum Nc-
Spain7 infection in non-pregnant mice, dams and pups
BALB/c mice were treated with buparvaquone (BPQ) in corn oil or with corn oil 
alone (Placebo), infected with Nc-Spain7, or were neither treated nor infected 
(no treatment), and euthanized as described in Section “Materials and methods”. 
Adults and surviving pups were tested for the presence of N. caninum in their 
brains by real time PCR. Pups that had died before the end of the experiment 
were considered as Nc positive. Respective numbers of animals in BPQ and 
placebo groups were compared by Chi square tests (*** p > 0.1, +p < 0.1,  
* p < 0.05, ** p < 0.001).
a Proportion of pups born dead or that died within the two first days post 
partum.
b Proportion of pups dead from day 3 to 30 pp, considered as Nc positive.
Parameter BPQ Placebo No treatment
Non‑pregnant females
 Number 8 8 7
 Clinical signs 0/8 0/8 0/7
 Mortality 0/8 0/8 0/7
 Seropositive 8/8 8/8 0/7
 Nc positive 2/8* 8/8 0/7
Dams and pups
 Number of dams 8 8 8
 Clinical signs 0/8+ 5/8 0/8
 Mortality 0/8*** 1/8 0/8
 Seropositive dams 8/8 8/8 0/8
 Nc positive dams 6/8*** 8/8 0/8
 Pregnancy rate 8/16 8/16 8/15
 Total number of pups 46 43 47
 Litter size average 46/8*** 43/8 47/8
 Neonatal mortalitya 1/46*** 2/43 0/47
 Postnatal mortalityb 18/45** 40/41 0/47
Nc positive pups 25/45** 41/41 0/47
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but to chronic infection followed by vertical transmis-
sion in dams [31], we demonstrate that in the short term, 
buparvaquone reduces the cerebral parasite load– as 
seen in the non-pregnant mice that were euthanized at 
3  weeks pi. However, in the longer term, as seen in the 
dams that were euthanized 30  days after birth, that is, 
44  days pi, no reduction in the cerebral parasite load 
was evident. This confirms earlier observations that 
buparvaquone is parasiticidal against N. caninum only 
after long term treatment [30]. Thus, 6  days of treat-
ment is too short to eradicate the parasite from the 
dams, but the action of the drug during this short time 
span is sufficient to consistently impair vertical transmis-
sion to the offspring as evidenced by a significantly lower 
cerebral parasite load and a lower mortality in the off-
spring. Under the conditions in which we run our in vivo 
experiments (SPF animals, controlled access, qualified 
personnel), in uninfected, untreated animals, postnatal 
mortality does not occur. In the vertical transmission 
model [31], postnatal mortality occurs only upon dose 
dependent infection of the dams. Pups of infected dams 
die within 3  weeks; pups of not infected dams survive. 
The model is reproducible as shown in a more recent 
study [39].
In conclusion, this study shows that repurposing of 
established drugs facilitates the identification of com-
pounds that may be applied for treatment of neospo-
rosis, thus avoiding a long and costly drug development 
process. Other examples of potentially interesting com-
pounds identified earlier through this avenue, and pro-
viding interesting results both in  vitro and in  vivo are 
miltefosine [40] and compounds belonging to the class 
of bumped kinase inhibitors (BKIs) that act against cal-
cium-dependent protein kinase 1, a target that is found in 
most apicomplexans [32, 39]. BKIs were originally devel-
oped to combat malaria [41]. Buparvaquone is already 
in use against Theileria infections in cattle in endemic 
Figure 3 Cerebral parasite load in non-pregnant and pregnant 
mice treated with buparvaquone. BALB/c mice were infected with 
Nc‑Spain7 tachyzoites and subsequently treated with buparvaquone 
(BPQ) in corn oil or corn oil only (Placebo) as detailed in Section 
“Materials and methods”. Non‑pregnant mice were euthanized 
3 weeks pi, dams were euthanized 30 days post partum (pp), thus 
44 days pi. After euthanasia, brains were collected and the amount of 
tachyzoites was determined by quantitative PCR and are presented 
as box plots (**p < 0.001; Kruskal–Wallis‑test). A non pregnant mice, 
B dams.
Figure 4 Anti total N. caninum IgG serum levels. Balb/c mice 
were treated as described in Figure 3 (BPQ, Placebo) or left untreated. 
Serum samples were taken following euthanasia of non pregnant 
females (A) or dams (B). ELISA wells were coated with Neospora 
caninum crude antigen. Values are presented as box‑plots. Groups 
labelled with different letters are significantly different (p < 0.005; 
Kruskal–Wallis‑test followed by Wilcoxon rank sum test).
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countries. Thus, it would be of interest to determine the 
incidence of neosporosis in buparvaquone treated cat-
tle in those regions as compared to a control population 
that has not been treated. Moreover, studies in cattle will 
show whether buparvaquone treatments are able to erad-
icate N. caninum from the mother cows or whether they 
reduce the parasite to a low level chronic infection which 
may reactivate as soon as drug treatment is withdrawn. 
After establishment of a suitable treatment scheme, 
the effects on vertical transmission in cattle could be 
determined.
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both of which were infected with Nc‑Spain7 isolate of N. caninum. As 
a parameter for survival, the Kaplan–Meier‑estimator (KME) is shown. 
The differences of BPQ and placebo survival curves were highly sig‑
nificant (log‑rank‑test; p < 10−12). In the untreated group (No treat.), 
no pup died (dotted line).
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